Patritumab Deruxtecan for EGFR-Mutated NSCLC After EGFR TKI Therapy and Platinum-Based Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
J. Clin. Oncol 2023 Sep 10;[EPub Ahead of Print], HA Yu, Y Goto, H Hayashi, E Felip, J Chih-Hsin Yang, M Reck, K Yoh, SH Lee, L Paz-Ares, B Besse, P Bironzo, DW Kim, ML Johnson, YL Wu, T John, S Kao, T Kozuki, E Massarelli, J Patel, E Smit, KL Reckamp, Q Dong, P Shrestha, PD Fan, P Patel, A Sporchia, DW Sternberg, D Sellami, PA JänneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.